| Varian ProBeam Proton Therapy System Clinical Trial (Shandong) (NCT06340815) | Varian, a Siemens Healthineers Company | 2022-07-20 |
| 68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG (NCT05543317) | The First Affiliated Hospital of Xiamen University | 2022-07-01 |
| Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies (NCT05221320) | BioMed Valley Discoveries, Inc | 2022-05-26 |
| Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer (NCT05392205) | The First Affiliated Hospital of Xiamen University | 2022-03-01 |
| A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors (NCT05082610) | Hummingbird Bioscience | 2022-02-28 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) (NCT05103358) | Aadi Bioscience, Inc. | 2022-02-15 |
| A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors (NCT05108623) | MiNK Therapeutics | 2022-01-28 |
| Varian ProBeam Proton Therapy System China Clinical Trial (Hefei) (NCT05463055) | Varian, a Siemens Healthineers Company | 2021-12-26 |
| [18F]FPIA PET/CT Imaging in Patients With Solid Tumours (NCT04717674) | University College, London | 2021-12-07 |
| 68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer (NCT05160051) | University Hospital, Essen | 2021-12-01 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (NCT05094804) | OncoResponse, Inc. | 2021-09-09 |
| BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors (NCT04819373) | Eikon Therapeutics | 2021-08-30 |
| Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT04840394) | Eikon Therapeutics | 2021-06-22 |
| Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X) (NCT04788147) | RefleXion Medical | 2021-03-26 |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies (NCT04640246) | Taiga Biotechnologies, Inc. | 2021-01-25 |
| First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors (NCT04528836) | Navire Pharma Inc., a BridgeBio company | 2020-11-12 |
| Follow-up of Actual Patient Care Site Two Months After Hospitalisation Compared With Their Expressed Choice Regarding Subsequent Care Site (RESPECT) (NCT04628234) | Institut de cancérologie Strasbourg Europe | 2020-07-04 |
| An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors (NCT04443088) | Shenzhen Ionova Life Sciences Co., Ltd. | 2020-06-26 |
| Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma (NCT04367948) | Peking University Cancer Hospital & Institute | 2020-05-01 |
| BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (NCT04196530) | Eikon Therapeutics | 2019-11-21 |
| Comparison of FDG and FAPI in Patients With Various Types of Cancer (NCT04416165) | The First Affiliated Hospital of Xiamen University | 2019-10-20 |
| Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer (NCT04750772) | Peking University Cancer Hospital & Institute | 2019-10-16 |
| Biomarkers of Renal Cancer (NCT05785052) | Biorek S.R.L. | 2019-06-11 |
| Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors (NCT03911557) | John L. Villano, MD, PhD | 2019-06-08 |
| Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (NCT03985072) | Andes Biotechnologies | 2019-04-26 |
| GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma (NCT03731390) | Chinese Academy of Medical Sciences | 2018-11-01 |
| BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (NCT03486301) | Eikon Therapeutics | 2018-02-15 |
| Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors (NCT03454035) | UNC Lineberger Comprehensive Cancer Center | 2018-01-30 |
| Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR) (NCT04095091) | University of Wisconsin, Madison | 2017-09-14 |
| Analysis of Chemical Pattern Exhaled by Different Neoplasms Through Chemoresistive Nanostructured Sensors (NCT03929185) | University Hospital of Ferrara | 2017-07-13 |
| A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) (NCT01358331) | Merck Sharp & Dohme LLC | 2011-11-04 |
| Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients (NCT05974410) | AVM Biotechnology Inc | |